Key Points Net loss attributable to common stockholders totaled $20.7 million for the three months ended June 30, 2025. Net loss attributable to common stockholders was $20.7 million for the three ...

Indian pharmaceutical companies are preparing to launch generic versions of Novo Nordisk's weight-loss drug, semaglutide, potentially reducing its price by up to 80%.